NeuroSense Therapeutics Ltd. (NasdaqCM: NRSN)
Health Care · Biotechnology · IL
$0.41
+8.69% today · -67.1% 1Y
NeuroSense Therapeutics Ltd. (NasdaqCM: NRSN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.91M and employs 17 people.
Over the last twelve months the share price has lost 67.1%, trading between 0.25 and 1.98.
Tweenvest scores NeuroSense Therapeutics Ltd. across four factors: quality 13/100. Its strongest factor is quality.
NRSN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.91M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.44
- Dividend yield
- —
- Beta (5Y)
- 1.60
- 52-week high
- $1.98
- 52-week low
- $0.25
- Avg volume (3M)
- —
- Shares outstanding
- 36.97M
- Employees
- 17
- Next earnings
- —
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
- ISIN
- IL0011809592
- Founded
- 2017
- Listed since
- Dec 9, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.